Walter Eisner • Mon, December 29th, 2014
Osiris Therapeutics, Inc. and Stryker Corporation have entered into an exclusive, worldwide partnership for the commercialization and development of Osiris’ viable bone matrix tissue form.
Under the agreement announced on December 22, 2014, Stryker has exclusive rights to BIO4, a bone allograft that contains both viable cells and growth factors. According to the announcement, BIO4 “is a safe alternative to autografts that minimizes the potential for harvest site co-morbidities. BIO4 is composed of a structural extracellular matrix, osteogenic and angiogenic growth factors, endogenous mesenchymal stem cells and osteoblasts. It possesses osteoconductive, osteoinductive, osteogenic and angiogenic properties that are required for bone repair and regeneration.”
Osiris will be responsible for manufacturing, continued research and product improvements while Stryker will be responsible for the commercialization and marketing of the product. “To demonstrate the differentiating benefits and ensure the continued success and growth of this innovative product, both organizations will collaborate on the design and conduct of future clinical development programs.”
BIO4 was developed by Osiris, also the creator of the first cellular allograft, utilizing their proprietary Biosmart cryopreservation technology. “It is ready-to-use out of the package and has differentiated handling compared to other products currently on the market. Originally branded as OvationOS, Osiris’ viable bone matrix tissue form will now be marketed by Stryker under the brand name BIO4.”